Prevenox on osteoarthritis

Effects of Prevenox (D-003) on symptoms of osteoarthritis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

RPCEC

Registry ID

RPCEC00000170

Enrollment

Registered

2013-09-20

Start date

2012-02-14

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis symptoms

Interventions

Control Group: Placebo of Prevenox 2 oral tablets daily for 6 weeks at breakfast. Study Group: Prevenox 2 oral tablets (5mg each) daily for 6 weeks at breakfast. Subjects who did not improve sym

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Subjects of both sexes 2. aged between 20 and 80 years 3. Subjects with symptoms of OA (joint pain in hip, spine, limbs and / or phalanges) 4. Subjects who signed the informed consent. 5. Subjects who qualified in Scales I-III of the American Association of Rheumatology 6. Subjects who had a WOMAC scale score = 30.

Exclusion criteria

Exclusion criteria: 1. Existence of other forms of arthritis, 2. Arthroplasty or orthopedic surgery in the last three years 3. Transplanted 4. Subjects with active liver or kidney disease 5. Neoplasms diagnosed, 6. Severe hypertension 7. Diabetes mellitus uncompensated 8. Hospitalization for any cause in the previous 6 months, 9. Subjects with fasting glucose> 7 mmol / L 10. Subjects with usual clinical history of allergy to drugs 11. Subjects with any other special condition that jeopardize their health and their lives during the study.

Design outcomes

Primary

Measure	Time frame
Health Status (WOMAC Questionnaire. 0-Best Score between health status and 96-worst health status). Measuring Time: Before starting treatment and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks	—

Secondary

Measure	Time frame
Pain (WOMAC Questionnaire. Value between 0 and 20 points). Measuring time: at baseline and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks Stiffness (WOMAC Questionnaire. Value from 0 to 8 points). Measuring time:at baseline and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks Physical Activity Questionnaire(WOMAC. Value between 0 and 68 points). Measuring time: at baseline and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks Pain (Visual Analogy Scale- VAS-. Value between 0-no pain-worst 100 points bearable pain). Measuring time:at baseline and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks Adverse events (description (name of the event), intensity (mild-moderate, severe), causality (definitely related, probably related, possibly related, not related)). Measuring time: At the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks.	—

Measure

Time frame

Pain (WOMAC Questionnaire. Value between 0 and 20 points). Measuring time: at baseline and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks Stiffness (WOMAC Questionnaire. Value from 0 to 8 points). Measuring time:at baseline and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks Physical Activity Questionnaire(WOMAC. Value between 0 and 68 points). Measuring time: at baseline and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks Pain (Visual Analogy Scale- VAS-. Value between 0-no pain-worst 100 points bearable pain). Measuring time:at baseline and at the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks Adverse events (description (name of the event), intensity (mild-moderate, severe), causality (definitely related, probably related, possibly related, not related)). Measuring time: At the end of the 1st, 2nd, 3rd, 4th, 5th and 6th weeks.

—

Countries

Cuba

Contacts

Public ContactSarahi Mendoza Castaño

Center of Natural Products, Nacional Center for Scientific Researchs

sarahi.mendoza@cnic.edu.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Aug 15, 2026